转换为法西单抗治疗的预处理新生血管性年龄相关性黄斑变性患者的一年结局：瑞士视网膜研究网络报告

One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

作者信息

Grimaldi Gabriela, Ambresin Aude, Pfister Isabel B, Schild Christin, Plasencia Christina, Hatz Katja, Stillenmunkes Richard, Munk Marion R, Paris Arianna, Menghini Moreno, Artemiev Dmitri, Ebneter Andreas, Cattaneo Jennifer, de Oliveira Figueiredo Eva C, Eandi Chiara M, Fröhlich Jacqueline, Feltgen Nicolas, Spitznagel Tahm, Somfai Gábor Márk, Cozzi Mariano, Zweifel Sandrine, Weinberger Andreas, Garweg Justus G

机构信息

Department of Ophthalmology, Institute of Clinical Neurosciences of Southern Switzerland (INSI), Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.

Swiss Visio Montchoisi, Lausanne, Switzerland; Swiss Visio Retina Research Center, Lausanne, Switzerland.

出版信息

Ophthalmol Retina. 2025 Sep;9(9):838-847. doi: 10.1016/j.oret.2025.03.015. Epub 2025 Mar 24.

DOI:10.1016/j.oret.2025.03.015

PMID:40139459

Abstract

PURPOSE

To report the efficacy and safety of switching to faricimab in a real-world, Swiss cohort of patients with pretreated neovascular age-related macular degeneration (nAMD).

DESIGN

Retrospective, multicenter, longitudinal observational study conducted at 11 centers of the Swiss Retina Research Network.

SUBJECTS

We included 353 eyes of 325 patients who were switched to intravitreal faricimab after prior anti-VEGF therapy and followed for a minimum of 12 months between May 1, 2022, and October 30, 2024.

METHODS

Demographic characteristics, baseline functional and OCT findings, treatment history, and outcomes at 12 months after switch to faricimab were extracted from the patients' electronic case report forms.

MAIN OUTCOME MEASURES

Change in best-corrected visual acuity (BCVA), central subfield thickness (CST), presence of retinal fluid (RF) and pigment epithelial detachment, treatment intervals, and safety signals.

RESULTS

Twelve months after switch, mean BCVA remained unchanged, whereas mean CST decreased from 315.3 to 263.9 μm (P < 0.01). Fast drying (absence of RF) after 1 faricimab injection was observed in 134 eyes (38%) and correlated positively with the treatment interval at 12 months (r(301) = 0.24; P < 0.01). After 12 months, 169 (47.9%) eyes demonstrated the absence of RF compared with 10.2% at switch. Mean treatment interval increased from 5.8 ± 2.5 weeks at switch to 8.3 ± 4.2 weeks at 12 months, and extended treatment intervals (≥12 week) were achieved in 20% of patients. Mild intraocular inflammation was reported in 1.7% of cases.

CONCLUSIONS

Switching to faricimab in pretreated nAMD led to sustained anatomic improvements and stabilization of BCVA, with a substantial reduction in RF compared with baseline. Our results suggest the potential benefits of this switching strategy based on real-world data.

FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

摘要

目的

报告在瑞士一个真实世界队列中，对先前接受过治疗的新生血管性年龄相关性黄斑变性（nAMD）患者改用法西单抗的疗效和安全性。

设计

在瑞士视网膜研究网络的11个中心进行的回顾性、多中心、纵向观察性研究。

研究对象

我们纳入了325例患者的353只眼，这些患者在先前接受抗VEGF治疗后改用玻璃体内注射法西单抗，并于2022年5月1日至2024年10月30日期间进行了至少12个月的随访。

方法

从患者的电子病例报告表中提取人口统计学特征、基线功能和光学相干断层扫描（OCT）结果、治疗史以及改用法西单抗后12个月时的结局。

主要观察指标

最佳矫正视力（BCVA）、中心子野厚度（CST）、视网膜液（RF）的存在情况和色素上皮脱离、治疗间隔以及安全信号的变化。

结果

改用后12个月，平均BCVA保持不变，而平均CST从315.3μm降至263.9μm（P<0.01）。134只眼（38%）在注射1次法西单抗后观察到快速干燥（无RF）情况，且与12个月时的治疗间隔呈正相关（r(301)=0.24；P<0.01）。12个月后，169只眼（47.9%）无RF，而改用时这一比例为10.2%。平均治疗间隔从改用时的5.8±2.5周增加至12个月时的8.3±4.2周，20%的患者实现了延长治疗间隔（≥12周）。1.7%的病例报告有轻度眼内炎症。